Acumen Pharmaceuticals Inc (ABOS) - Total Liabilities
Based on the latest financial reports, Acumen Pharmaceuticals Inc (ABOS) has total liabilities worth $52.40 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Acumen Pharmaceuticals Inc generate cash to assess how effectively this company generates cash.
Acumen Pharmaceuticals Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Acumen Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Check Acumen Pharmaceuticals Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Acumen Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Acumen Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Les Hotels Bav
PA:ALLHB
|
France | €22.71 Million |
|
Sriracha Construction Public Company Limited
BK:SRICHA
|
Thailand | ฿1.58 Billion |
|
GAMSUNG Corporation Co. Ltd
KQ:036620
|
Korea | ₩51.63 Billion |
|
Epsilon Energy Ltd
NASDAQ:EPSN
|
USA | $26.07 Million |
|
KGL Resources Ltd
AU:KGL
|
Australia | AU$1.47 Million |
|
Oando PLC
JSE:OAO
|
South Africa | ZAC7.26 Trillion |
|
Readly International AB
ST:READ
|
Sweden | Skr223.73 Million |
|
HB Technology CO.LTD
KQ:078150
|
Korea | ₩92.24 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Acumen Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Acumen Pharmaceuticals Inc (ABOS) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.74 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Acumen Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Acumen Pharmaceuticals Inc (2019–2025)
The table below shows the annual total liabilities of Acumen Pharmaceuticals Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $52.40 Million | -8.35% |
| 2024-12-31 | $57.18 Million | +32.50% |
| 2023-12-31 | $43.15 Million | +452.38% |
| 2022-12-31 | $7.81 Million | +51.78% |
| 2021-12-31 | $5.15 Million | -91.83% |
| 2020-12-31 | $63.02 Million | +236.25% |
| 2019-12-31 | $18.74 Million | -- |
About Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target s… Read more